Tenax Therapeutics (TENX) Revenue (2011 - 2015)

Tenax Therapeutics (TENX) reported Revenue of $49286.0 for Q2 2015, down 62.66% sequentially from $132000.0 in Q2 2013.

Tenax Therapeutics (TENX) Revenue (2011 - 2015) Analysis & Trends

Tenax Therapeutics (TENX) has 4 years of Revenue data on file, last reported at $49286.0 in Q2 2015.

For the quarter ending Q2 2015, Revenue changed N/A year-over-year to $49286.0; the trailing twelve-month figure through Jun 2016 stood at $49286.0 (down 94.6% YoY), and the FY2015 full-year result was $49286.0, changed N/A from the prior year.
Revenue eased to $49286.0 in Q2 2015, from $132000.0 in the prior quarter.
In the past five years, Revenue ranged from a high of $509435.0 in Q4 2012 to a low of $24873.0 in Q3 2011.
A 4-year average of $154383.2 and a median of $113743.5 in 2012 frame the typical range for Revenue.
Across the five-year window, Revenue surged 971.64% in 2012 and jumped 38.24% in 2013, its largest moves.
Tracing TENX's Revenue over 4 years: stood at $53371.0 in 2011, then soared by 854.52% to $509435.0 in 2012, then plunged by 74.09% to $132000.0 in 2013, then plunged by 62.66% to $49286.0 in 2015.
Business Quant data shows TENX's Revenue at $49286.0 in Q2 2015, $132000.0 in Q2 2013, and $222388.0 in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	1.51 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.99 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	3.61 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.56 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Tenax Therapeutics	67,856.40	67,856.40	-	-

Download Data